Gilead Sciences Portfolio holdings
Gilead Sciences is an American biopharmaceutical company that researches and develops antiviral drugs for HIV/AIDS, hepatitis B and C, influenza and COVID-19. Michael Riordan, a doctor who was then an associate at the venture firm Menlo Ventures, founded it in 1987 as Oligogen, a name pointing to oligonucleotides, small strands of DNA. Riordan used Oligogen only while clearing a trademark issue with a California nonprofit, and he took the Gilead name from the Balm of Gilead, which he first met in a Lanford Wilson play. Gilead discovered the flu drug Tamiflu and licensed it to Roche, and its 2011 purchase of Pharmasset brought it sofosbuvir, approved in 2013 as the hepatitis C treatment Sovaldi. In 2017 Gilead said it would acquire Kite Pharma as its entry into cell therapy, a deal that had produced two lymphoma treatments, Yescarta and Tecartus, by 2022.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcus Biosciences
RCUS
|
+$15.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ImageneBio Inc
IMA
|
+$1.22M |
| 2 |
Agenus
AGEN
|
+$635K |
| 3 |
BRNS
Barinthus Biotherapeutics
BRNS
|
+$257K |
| 4 |
Kronos Bio
KRON
|
+$179K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.86% |
| 2 | Financials | 0.14% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
DELISTED
Arcellx
ACLX
| $441M | 37.32% |
6,720,803
| – | – |
2024 Q4
1 quarter
|
|
2
Lakefront Biotherapeutics American Depositary Shares
LKFT
$2.13B
| $419M | 35.5% |
16,707,477
| – | – |
2024 Q4
1 quarter
|
|
|
3
Arcus Biosciences
RCUS
$2.32B
| $247M | 20.88% |
31,424,760
+1,363,636
| +5% | +$15.8M |
2024 Q4
1 quarter
|
|
4
Assembly Biosciences
ASMB
$410M
| $21.1M | 1.79% |
2,209,471
| – | – |
2024 Q4
1 quarter
|
|
5
DELISTED
Merus
MRUS
| $19M | 1.61% |
452,527
| – | – |
2024 Q4
1 quarter
|
|
6
Kyverna Therapeutics
KYTX
$351M
| $7.96M | 0.67% |
4,126,119
| – | – |
2024 Q4
1 quarter
|
|
7
Tango Therapeutics
TNGX
$3.83B
| $6.65M | 0.56% |
4,854,443
| – | – |
2024 Q4
1 quarter
|
|
8
Xilio Therapeutics
XLO
$52.8M
| $6.6M | 0.56% |
650,389
| – | – |
2024 Q4
1 quarter
|
|
9
Kalaris Therapeutics
KLRS
$48.3M
| $5.81M | 0.49% |
723,273
| – | – |
2024 Q4
1 quarter
|
|
10
DELISTED
HOOKIPA Pharma
HOOK
| $2.03M | 0.17% |
1,875,945
| – | – |
2024 Q4
1 quarter
|
|
11
Allogene Therapeutics
ALLO
$408M
| $1.69M | 0.14% |
1,156,689
| – | – |
2024 Q4
1 quarter
|
|
12
Cypherpunk Technologies Inc
CYPH
$321M
| $1.62M | 0.14% |
5,319,148
| – | – |
2024 Q4
1 quarter
|
|
|
13
ImageneBio Inc
IMA
$46.5M
| $1.48M | 0.13% |
96,595
-70,767
| -42% | -$1.22M |
2024 Q4
1 quarter
|
|
|
BRNS
14
DELISTED
Barinthus Biotherapeutics
BRNS
| $360K | 0.03% |
369,855
-250,496
| -40% | -$257K |
2024 Q4
1 quarter
|
|
|
15
Agenus
AGEN
$309M
| – | – |
-231,663
| Closed | -$635K | – |
|
|
16
DELISTED
Kronos Bio
KRON
| – | – |
-188,567
| Closed | -$179K | – |
|
Similar funds
Gilead Sciences's Q1 2025 Portfolio in Review
As of Q1 2025, Gilead Sciences held 16 positions worth $1.18B, down 24% from $1.55B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Gilead Sciences's Q1 2025 filing shows 1 increased, 2 reduced and 2 closed positions. The largest sale was ImageneBio Inc, an estimated $1.22M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.
- Gilead Sciences added most to Arcus Biosciences in Q1 2025, an estimated $15.8M increase.
- Gilead Sciences's biggest Q1 2025 reduction was ImageneBio Inc, cutting an estimated $1.22M.
- Gilead Sciences fully exited Agenus in Q1 2025, selling an estimated $635K.
- Gilead Sciences's ten largest holdings make up 100% of its $1.18B portfolio in Q1 2025.
- Gilead Sciences opened 0 new positions and closed 2 in Q1 2025.
- Gilead Sciences's portfolio value fell 24% quarter-over-quarter to $1.18B.
Based on Gilead Sciences's 13F filing for Q1 2025, filed 13 May 2025.